Announcement on the "Quality Return Dual Improvement" Action Plan
Securities Code: 300653
Securities Abbreviation: Zhenghai Biological
Announcement Number: 2026-014
Yantai Zhenghai Biological Technology Co., Ltd. (hereinafter referred to as "the Company") has formulated the "Quality Return Dual Improvement" action plan to uphold the interests of all shareholders, enhance investor confidence, and promote sustainable development. This initiative aligns with the guiding principles from the Central Political Bureau meeting and the State Council's executive meeting, which emphasize the need to enhance the quality and investment value of listed companies and implement effective measures to stabilize the market and confidence.
1. Deepen Core Business and Promote High-Quality Development
Founded in 2003, the Company is a national high-tech enterprise and a key R&D program undertaking unit. As one of the earliest companies in China to focus on regenerative medicine, it specializes in the R&D, production, and sales of Class II and III medical devices and drug-device combination products. The Company has launched products such as oral repair membranes, absorbable dura mater patches, active biological bone, skin repair membranes, bone repair materials, surgical packing sponges, and self-etching adhesives, which are widely used in oral and maxillofacial surgery, neurosurgery, orthopedics, and trauma surgery, earning the trust and support of millions of doctors and patients.
The Company’s self-developed active biological bone product is the first bone repair material approved in China as a drug-device combination, successfully establishing a low-dose overall and high-efficiency local bone regeneration directional repair system. In early 2026, the Company’s new generation of oral bone repair material, calcium silicate bioceramic oral bone repair material, received the "Medical Device Registration Certificate," becoming the first additive manufacturing oral bone repair product in China, providing a more precise and efficient solution for repairing complex bone defects in the oral environment.
In the future, the Company will continue to deepen its focus on the regenerative medicine field, adhering to its mission of "reshaping the body's self-healing power and making regeneration dreams a reality." It will strengthen its strategic role of "high-end positioning, micro-technical focus, and precise marketing," while optimizing existing business, introducing strategic growth pipelines, transforming marketing precision, and integrating internal and external resources to promote high-quality sustainable development.
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.